Mylan (MYL) Stock Price, News & Analysis

Company Overview

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Key Stats

• Today's Range: $15.86 to $15.86
• 50-Day Range: $14.37 to $15.86
• 52-Week Range: $12.75 to $23.11
• Volume: 4,016 shs
• Average Volume: 6.49 million shs
• Market Capitalization: $8.59 billion
• P/E Ratio: 29.92
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mylan Stock Analysis - MarketRank™

Mylan scored higher than 22% of companies evaluated by MarketBeat, and ranked 805th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mylan.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 0.90%

Earnings Growth

Earnings for Mylan are expected to grow by 0.90% in the coming year, from $4.46 to $4.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mylan is 29.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mylan is 29.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.47.

Price to Earnings Growth Ratio

Mylan has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Mylan has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MYL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mylan does not currently pay a dividend.

Dividend Growth

Mylan does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -2.51

Short Interest

There is no current short interest data available for MYL.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Mylan this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mylan insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.59% of the stock of Mylan is held by insiders.

Percentage Held by Institutions

88.18% of the stock of Mylan is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYL Stock Analysis - Frequently Asked Questions

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) posted its earnings results on Friday, November, 6th. The company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.15. The firm's revenue was up .4% on a year-over-year basis.

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mylan investors own include Bristol Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Netflix (NFLX) and Micron Technology (MU).

Company Calendar

• Last Earnings: 11/06/2020
• Today: 10/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MYL
• CIK: 1623613
• Web: www.mylan.com
• Phone: 724-514-1800
• Fax: N/A
• Employees: 35,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $4.42
• Trailing P/E Ratio: 29.92
• Forward P/E Ratio: 3.55
• P/E Growth: 2.01
• Net Income: $16.80 million
• Net Margins: 2.35%
• Pretax Margin: N/A
• Return on Equity: 20.43%
• Return on Assets: 7.72%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 0.93
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $11.50 billion
• Price / Sales: 0.75
• Cash Flow: $8.76 per share
• Price / Cash Flow: 1.81
• Book Value: $23.02 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 541,546,000
• Free Float: N/A
• Market Cap: $8.59 billion
• Optionable: Optionable
• Beta: 1.45